Table 4.
Histometric, neuropathology, clinical and BIE correlates
| mCERADSOT | Amyloid phase | % Amyloid IHC | Dx AD (NIA-RI) | Dx AD (NIA-AA) | Braak stage | Cortical atrophy | SUVR | Dementia | BIE positivity | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (Quantitative) | (Ordinal) | (Quantitative) | (Ordinal) | (Ordinal) | (Ordinal) | (Ordinal) | (Quantitative) | (Nominal) | (Nominal) | ||
| P < 0.0001 | P < 0.0001 | P = 0.0005 | P < 0.0001 | P < 0.0001 | P < 0.0001 | P = 0.2518 | P < 0.0001 | P = 0.0009 | P < 0.0001 | CERAD | (Ordinal) |
| P < 0.0001 | P = 0.0014 | P < 0.0001 | P < 0.0001 | P < 0.0001 | P = 0.3569 | P < 0.0001 | P = 0.0021 | P < 0.0001 | mCERADSOT | (Quantitative) | |
| P < 0.0001 | P < 0.0001 | P < 0.0001 | P < 0.0001 | P = 0.6275 | P < 0.0001 | P < 0.0001 | P < 0.0001 | Amyloid Phase | (Ordinal) | ||
| P = 0.0001 | P < 0.0001 | P = 0.0001 | P = 0.9266 | P < 0.0001 | P = 0.8746 | P < 0.0001 | % amyloid IHC | (Quantitative) | |||
| P < 0.0001 | P < 0.0001 | P = 0.2087 | P < 0.0001 | P < 0.0001 | P < 0.0001 | AD (NIA-RI) | (Ordinal) | ||||
| P < 0.0001 | P = 0.2758 | P < 0.0001 | P < 0.0001 | P < 0.0001 | AD (NIA-AA) | (Ordinal) | |||||
| P = 0.4195 | P < 0.0001 | P < 0.0001 | P < 0.0001 | Braak Stage | (Ordinal) | ||||||
| P = 0.1778 | P = 0.4006 | P = 0.7397 | Cortical atrophy | (Ordinal) | |||||||
| P = 0.0041 | P < 0.0001 | SUVR | (Quantitative) | ||||||||
| P < 0.0001 | Dementia | (Nominal) |
mCERAD SOT modified CERAD Standard of Truth, IHC Immunohistochemistry, Dx AD (NIA-RI) Neuropathological diagnosis of AD likelihood using the National Institute of Ageing – Reagan Institute criteria [9], Dx AD (NIA-AA) Neuropathological diagnosis of AD likelihood using the National Institute of Ageing – Alzheimer’s Association criteria [8], SUVR Standard retention value ratio normalised to the cerebellar cortex, BIE Blinded Image evaluation of PET images, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
Statistical tests were performed as indicated in the insert panel. mCERADSOT, % area amyloid IHC and SUVR values are continuous variables. All other variables are either categorical; CERAD (None, Sparse, Moderate, Frequent); Amyloid Phase (phases 0, 1, 2, 3, 4 and 5); Dx AD (NIA-RI) (Normal, Low, Intermediate or High - likelihood of AD), Dx AD (NIA-RI) (Not, Low, Intermediate or High – level of AD neuropathologic change), Braak Stage (Stage 0, I, II, III, IV, V and VI); Cortical atrophy (None, Mild, Moderate, Severe), or nominal; Dementia (Yes or No); BIE positivity (Normal Abnormal). All tests were performed using Spearman except BIE positivity vs Dementia which was perfomed using Chi-square test. Plots for some BIE positivity correlations are presented in Figs. 2 and 4